How personal loss and hope drove Elaine Maynard’s work in clinical trials and patient-centric technologies

Citius Pharma receives FDA approval for immunotherapy targeting rare blood cancer

Halda Therapeutics raises $126M to take 'hold and kill' precision cancer drugs to the clinic

Gilead gains accelerated FDA approval for rare liver disease treatment

FDA lifts hold on BioNTech and MediLink's ADC trial After safety revisions

Breakthrough delivery system could transform Alzheimer’s treatment

First bispecific CAR-T therapy for MS receives green light from FDA to start phase 1

Breaking News: Lecanemab approved in UK but unavailable on NHS

Highlights

array(40) {
  [0]=>
  string(4) "1939"
  ["article_id"]=>
  string(4) "1939"
  [1]=>
  string(108) "Kyowa Kirin Announces FDA Acceptance of Istradefylline (KW-6002) New Drug Application Resubmission in the US"
  ["article_title"]=>
  string(108) "Kyowa Kirin Announces FDA Acceptance of Istradefylline (KW-6002) New Drug Application Resubmission in the US"
  [2]=>
  string(150) "TOKYO--(BUSINESS WIRE)--Apr 4, 2019--Kyowa Hakko Kirin Co., Ltd. (TOKYO:4151, President and CEO: Masashi Miyamoto, “Kyowa Kirin”) announce"
  ["short_description"]=>
  string(150) "TOKYO--(BUSINESS WIRE)--Apr 4, 2019--Kyowa Hakko Kirin Co., Ltd. (TOKYO:4151, President and CEO: Masashi Miyamoto, “Kyowa Kirin”) announce"
  [3]=>
  string(252) "TOKYO--(BUSINESS WIRE)--Apr 4, 2019--Kyowa Hakko Kirin Co., Ltd. (TOKYO:4151, President and CEO: Masashi Miyamoto, “Kyowa Kirin”) announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmitted New Drug..."
  ["description"]=>
  string(252) "TOKYO--(BUSINESS WIRE)--Apr 4, 2019--Kyowa Hakko Kirin Co., Ltd. (TOKYO:4151, President and CEO: Masashi Miyamoto, “Kyowa Kirin”) announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmitted New Drug..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "9"
  ["rss_id"]=>
  string(1) "9"
  [14]=>
  string(201) "https://www.drugs.com/nda/kw_6002_190404.html?utm_source=ddc&utm_medium=rss&utm_campaign=Kyowa+Kirin+Announces+FDA+Acceptance+of+Istradefylline+%28KW-6002%29+New+Drug+Application+Resubmission+in+the+US"
  ["blog_url"]=>
  string(201) "https://www.drugs.com/nda/kw_6002_190404.html?utm_source=ddc&utm_medium=rss&utm_campaign=Kyowa+Kirin+Announces+FDA+Acceptance+of+Istradefylline+%28KW-6002%29+New+Drug+Application+Resubmission+in+the+US"
  [15]=>
  string(19) "2019-04-04 12:04:47"
  ["add_date"]=>
  string(19) "2019-04-04 12:04:47"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:35:51"
  ["create_at"]=>
  string(19) "2019-05-09 16:35:51"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Kyowa Kirin Announces FDA Acceptance of Istradefylline (KW-6002) New Drug Application Resu

TOKYO--(BUSINESS WIRE)--Apr 4, 2019--Kyowa Hakko Kirin Co., Ltd. (TOKYO:4151, President and CEO: Masashi Miyamoto, &ldqu

array(40) {
  [0]=>
  string(4) "1931"
  ["article_id"]=>
  string(4) "1931"
  [1]=>
  string(100) "FDA Approves Ibrance (palbociclib) for the Treatment of Men with HR+, HER2- Metastatic Breast Cancer"
  ["article_title"]=>
  string(100) "FDA Approves Ibrance (palbociclib) for the Treatment of Men with HR+, HER2- Metastatic Breast Cancer"
  [2]=>
  string(150) "April 4, 2019 -- Pfizer (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA"
  ["short_description"]=>
  string(150) "April 4, 2019 -- Pfizer (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA"
  [3]=>
  string(252) "April 4, 2019 -- Pfizer (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) to expand the indications for Ibrance (palbociclib) in combination with an aromatase inhibitor or..."
  ["description"]=>
  string(252) "April 4, 2019 -- Pfizer (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) to expand the indications for Ibrance (palbociclib) in combination with an aromatase inhibitor or..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "8"
  ["rss_id"]=>
  string(1) "8"
  [14]=>
  string(262) "https://www.drugs.com/newdrugs/fda-approves-ibrance-palbociclib-men-hr-her2-metastatic-breast-cancer-4943.html?utm_source=ddc&utm_medium=rss&utm_campaign=FDA+Approves+Ibrance+%28palbociclib%29+for+the+Treatment+of+Men+with+HR%2B%2C+HER2-+Metastatic+Breast+Cancer"
  ["blog_url"]=>
  string(262) "https://www.drugs.com/newdrugs/fda-approves-ibrance-palbociclib-men-hr-her2-metastatic-breast-cancer-4943.html?utm_source=ddc&utm_medium=rss&utm_campaign=FDA+Approves+Ibrance+%28palbociclib%29+for+the+Treatment+of+Men+with+HR%2B%2C+HER2-+Metastatic+Breast+Cancer"
  [15]=>
  string(19) "2019-04-04 08:04:33"
  ["add_date"]=>
  string(19) "2019-04-04 08:04:33"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:35:51"
  ["create_at"]=>
  string(19) "2019-05-09 16:35:51"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

FDA Approves Ibrance (palbociclib) for the Treatment of Men with HR+, HER2- Metastatic Bre

April 4, 2019 -- Pfizer (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) approved a supplemen

array(40) {
  [0]=>
  string(4) "1817"
  ["article_id"]=>
  string(4) "1817"
  [1]=>
  string(55) "EMA accepts Takeda application for subcutaneous Entyvio"
  ["article_title"]=>
  string(55) "EMA accepts Takeda application for subcutaneous Entyvio"
  [2]=>
  string(85) "The company proposes to make it available in both pre-filled syringe and pen options."
  ["short_description"]=>
  string(85) "The company proposes to make it available in both pre-filled syringe and pen options."
  [3]=>
  string(85) "The company proposes to make it available in both pre-filled syringe and pen options."
  ["description"]=>
  string(85) "The company proposes to make it available in both pre-filled syringe and pen options."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "4"
  ["rss_id"]=>
  string(1) "4"
  [14]=>
  string(95) "http://www.pharmatimes.com/news/ema_accepts_takeda_application_for_subcutaneous_entyvio_1283242"
  ["blog_url"]=>
  string(95) "http://www.pharmatimes.com/news/ema_accepts_takeda_application_for_subcutaneous_entyvio_1283242"
  [15]=>
  string(19) "2019-04-03 18:03:45"
  ["add_date"]=>
  string(19) "2019-04-03 18:03:45"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-04-08 15:10:57"
  ["create_at"]=>
  string(19) "2019-04-08 15:10:57"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

EMA accepts Takeda application for subcutaneous Entyvio

The company proposes to make it available in both pre-filled syringe and pen options.

array(40) {
  [0]=>
  string(4) "1915"
  ["article_id"]=>
  string(4) "1915"
  [1]=>
  string(130) "E-cigarette: Safety Communication - Related to Seizures Reported Following E-cigarette Use, Particularly in Youth and Young Adults"
  ["article_title"]=>
  string(130) "E-cigarette: Safety Communication - Related to Seizures Reported Following E-cigarette Use, Particularly in Youth and Young Adults"
  [2]=>
  string(150) "Audience: Consumers, Emergency Medicine, Health Professionals ISSUE: The FDA has become aware that some people who use e-cigarettes have experienced s"
  ["short_description"]=>
  string(150) "Audience: Consumers, Emergency Medicine, Health Professionals ISSUE: The FDA has become aware that some people who use e-cigarettes have experienced s"
  [3]=>
  string(251) "Audience: Consumers, Emergency Medicine, Health Professionals ISSUE: The FDA has become aware that some people who use e-cigarettes have experienced seizures, with most reports involving youth or young adult users. Seizures or convulsions are known..."
  ["description"]=>
  string(251) "Audience: Consumers, Emergency Medicine, Health Professionals ISSUE: The FDA has become aware that some people who use e-cigarettes have experienced seizures, with most reports involving youth or young adult users. Seizures or convulsions are known..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "7"
  ["rss_id"]=>
  string(1) "7"
  [14]=>
  string(300) "https://www.drugs.com/fda/e-cigarette-safety-communication-related-seizures-reported-following-e-cigarette-particularly-youth-14261.html?utm_source=ddc&utm_medium=rss&utm_campaign=E-cigarette%3A+Safety+Communication+-+Related+to+Seizures+Reported+Following+E-cigarette+Use%2C+Particularly+in+Youth+an"
  ["blog_url"]=>
  string(300) "https://www.drugs.com/fda/e-cigarette-safety-communication-related-seizures-reported-following-e-cigarette-particularly-youth-14261.html?utm_source=ddc&utm_medium=rss&utm_campaign=E-cigarette%3A+Safety+Communication+-+Related+to+Seizures+Reported+Following+E-cigarette+Use%2C+Particularly+in+Youth+an"
  [15]=>
  string(19) "2019-04-03 08:00:00"
  ["add_date"]=>
  string(19) "2019-04-03 08:00:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:35:50"
  ["create_at"]=>
  string(19) "2019-05-09 16:35:50"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

E-cigarette: Safety Communication - Related to Seizures Reported Following E-cigarette Use

Audience: Consumers, Emergency Medicine, Health Professionals ISSUE: The FDA has become aware that some people who use e

array(40) {
  [0]=>
  string(4) "1940"
  ["article_id"]=>
  string(4) "1940"
  [1]=>
  string(114) "Evoke Pharma Receives Complete Response Letter and Recommendations to Address Deficiencies from FDA for Gimoti NDA"
  ["article_title"]=>
  string(114) "Evoke Pharma Receives Complete Response Letter and Recommendations to Address Deficiencies from FDA for Gimoti NDA"
  [2]=>
  string(150) "SOLANA BEACH, Calif., April 02, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments f"
  ["short_description"]=>
  string(150) "SOLANA BEACH, Calif., April 02, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments f"
  [3]=>
  string(251) "SOLANA BEACH, Calif., April 02, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it has received a Complete Response Letter..."
  ["description"]=>
  string(251) "SOLANA BEACH, Calif., April 02, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it has received a Complete Response Letter..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "9"
  ["rss_id"]=>
  string(1) "9"
  [14]=>
  string(202) "https://www.drugs.com/nda/gimoti_190402.html?utm_source=ddc&utm_medium=rss&utm_campaign=Evoke+Pharma+Receives+Complete+Response+Letter+and+Recommendations+to+Address+Deficiencies+from+FDA+for+Gimoti+NDA"
  ["blog_url"]=>
  string(202) "https://www.drugs.com/nda/gimoti_190402.html?utm_source=ddc&utm_medium=rss&utm_campaign=Evoke+Pharma+Receives+Complete+Response+Letter+and+Recommendations+to+Address+Deficiencies+from+FDA+for+Gimoti+NDA"
  [15]=>
  string(19) "2019-04-03 06:04:56"
  ["add_date"]=>
  string(19) "2019-04-03 06:04:56"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:35:51"
  ["create_at"]=>
  string(19) "2019-05-09 16:35:51"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Evoke Pharma Receives Complete Response Letter and Recommendations to Address Deficiencies

SOLANA BEACH, Calif., April 02, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical c

array(40) {
  [0]=>
  string(4) "1976"
  ["article_id"]=>
  string(4) "1976"
  [1]=>
  string(103) "Antidepressants in the treatment of major depression: a changing landscape for clinical decision making"
  ["article_title"]=>
  string(103) "Antidepressants in the treatment of major depression: a changing landscape for clinical decision making"
  [2]=>
  string(152) "With publication of the update to the National Institute of Health and Care Excellence depression guideline postponed until late 2019, this article a"
  ["short_description"]=>
  string(152) "With publication of the update to the National Institute of Health and Care Excellence depression guideline postponed until late 2019, this article a"
  [3]=>
  string(283) "With publication of the update to the National Institute of Health and Care Excellence depression guideline postponed until late 2019, this article aims to examine the findings of the Cipriani et al. meta-analysis in the wider context of the management of depression in the UK."
  ["description"]=>
  string(283) "With publication of the update to the National Institute of Health and Care Excellence depression guideline postponed until late 2019, this article aims to examine the findings of the Cipriani et al. meta-analysis in the wider context of the management of depression in the UK."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "12"
  ["rss_id"]=>
  string(2) "12"
  [14]=>
  string(187) "https://www.pharmaceutical-journal.com/research/perspective-article/antidepressants-in-the-treatment-of-major-depression-a-changing-landscape-for-clinical-decision-making/20206214.article"
  ["blog_url"]=>
  string(187) "https://www.pharmaceutical-journal.com/research/perspective-article/antidepressants-in-the-treatment-of-major-depression-a-changing-landscape-for-clinical-decision-making/20206214.article"
  [15]=>
  string(19) "2019-04-02 23:54:00"
  ["add_date"]=>
  string(19) "2019-04-02 23:54:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:35:55"
  ["create_at"]=>
  string(19) "2019-05-09 16:35:55"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Antidepressants in the treatment of major depression: a changing landscape for clinical de

With publication of the update to the National Institute of Health and Care Excellence depression guideline postponed

array(40) {
  [0]=>
  string(4) "2383"
  ["article_id"]=>
  string(4) "2383"
  [1]=>
  string(41) "FDA to Modernize 510(k) Clearance Pathway"
  ["article_title"]=>
  string(41) "FDA to Modernize 510(k) Clearance Pathway"
  [2]=>
  string(153) "&#nl        The Food and Drug Administration is changing the most common way it approves new low- to moderate-risk medical devices for use in the United "
  ["short_description"]=>
  string(153) "&#nl        The Food and Drug Administration is changing the most common way it approves new low- to moderate-risk medical devices for use in the United "
  [3]=>
  string(171) "&#nl        The Food and Drug Administration is changing the most common way it approves new low- to moderate-risk medical devices for use in the United States. &#nl      "
  ["description"]=>
  string(171) "&#nl        The Food and Drug Administration is changing the most common way it approves new low- to moderate-risk medical devices for use in the United States. &#nl      "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "99"
  ["rss_id"]=>
  string(2) "99"
  [14]=>
  string(82) "https://www.assemblymag.com/articles/94822-fda-to-modernize-510k-clearance-pathway"
  ["blog_url"]=>
  string(82) "https://www.assemblymag.com/articles/94822-fda-to-modernize-510k-clearance-pathway"
  [15]=>
  string(19) "2019-04-02 20:00:00"
  ["add_date"]=>
  string(19) "2019-04-02 20:00:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:42:22"
  ["create_at"]=>
  string(19) "2019-05-09 16:42:22"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

FDA to Modernize 510(k) Clearance Pathway

&#nl The Food and Drug Administration is changing the most common way it approves new low- to moderate-risk medic

array(40) {
  [0]=>
  string(4) "1822"
  ["article_id"]=>
  string(4) "1822"
  [1]=>
  string(85) "Regulatory Reporting: What can Medical Device Manufacturers Learn from Big Pharma?"
  ["article_title"]=>
  string(85) "Regulatory Reporting: What can Medical Device Manufacturers Learn from Big Pharma?"
  [2]=>
  string(150) "Pharmaceutical companies have long been subject to the kinds of rigorous electronic reporting standards that will soon affect medical device manufactu"
  ["short_description"]=>
  string(150) "Pharmaceutical companies have long been subject to the kinds of rigorous electronic reporting standards that will soon affect medical device manufactu"
  [3]=>
  string(608) "
Pharmaceutical companies have long been subject to the kinds of rigorous electronic reporting standards that will soon affect medical device manufacturers. What can be gleaned from their experiences?
&#nl
The post Regulatory Reporting: What can Medical Device Manufacturers Learn from Big Pharma? appeared first on MedTech Intelligence.
&#nl"
  ["description"]=>
  string(608) "
Pharmaceutical companies have long been subject to the kinds of rigorous electronic reporting standards that will soon affect medical device manufacturers. What can be gleaned from their experiences?
&#nl
The post Regulatory Reporting: What can Medical Device Manufacturers Learn from Big Pharma? appeared first on MedTech Intelligence.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "98"
  ["rss_id"]=>
  string(2) "98"
  [14]=>
  string(124) "https://www.medtechintelligence.com/column/regulatory-reporting-what-can-medical-device-manufacturers-learn-from-big-pharma/"
  ["blog_url"]=>
  string(124) "https://www.medtechintelligence.com/column/regulatory-reporting-what-can-medical-device-manufacturers-learn-from-big-pharma/"
  [15]=>
  string(19) "2019-04-02 19:15:20"
  ["add_date"]=>
  string(19) "2019-04-02 19:15:20"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-04-15 14:56:01"
  ["create_at"]=>
  string(19) "2019-04-15 14:56:01"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Regulatory Reporting: What can Medical Device Manufacturers Learn from Big Pharma?

Pharmaceutical companies have long been subject to the kinds of rigorous electronic reporting standards that will soo

array(40) {
  [0]=>
  string(4) "1932"
  ["article_id"]=>
  string(4) "1932"
  [1]=>
  string(92) "FDA Approves Avaclyr (acyclovir ophthalmic ointment) for the Treatment of Herpetic Keratitis"
  ["article_title"]=>
  string(92) "FDA Approves Avaclyr (acyclovir ophthalmic ointment) for the Treatment of Herpetic Keratitis"
  [2]=>
  string(150) "NEW YORK–(BUSINESS WIRE) April 01, 2019 –The US Food and Drug Administration (FDA) has approved Fera Pharmaceuticals' New Drug Applica"
  ["short_description"]=>
  string(150) "NEW YORK–(BUSINESS WIRE) April 01, 2019 –The US Food and Drug Administration (FDA) has approved Fera Pharmaceuticals' New Drug Applica"
  [3]=>
  string(251) "NEW YORK–(BUSINESS WIRE) April 01, 2019 –The US Food and Drug Administration (FDA) has approved Fera Pharmaceuticals' New Drug Application (NDA) for Avaclyr (acyclovir ophthalmic ointment) 3% for the treatment of herpetic keratitis...."
  ["description"]=>
  string(251) "NEW YORK–(BUSINESS WIRE) April 01, 2019 –The US Food and Drug Administration (FDA) has approved Fera Pharmaceuticals' New Drug Application (NDA) for Avaclyr (acyclovir ophthalmic ointment) 3% for the treatment of herpetic keratitis...."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "8"
  ["rss_id"]=>
  string(1) "8"
  [14]=>
  string(250) "https://www.drugs.com/newdrugs/fda-approves-avaclyr-acyclovir-ophthalmic-ointment-herpetic-keratitis-4939.html?utm_source=ddc&utm_medium=rss&utm_campaign=FDA+Approves+Avaclyr+%28acyclovir+ophthalmic+ointment%29+for+the+Treatment+of+Herpetic+Keratitis"
  ["blog_url"]=>
  string(250) "https://www.drugs.com/newdrugs/fda-approves-avaclyr-acyclovir-ophthalmic-ointment-herpetic-keratitis-4939.html?utm_source=ddc&utm_medium=rss&utm_campaign=FDA+Approves+Avaclyr+%28acyclovir+ophthalmic+ointment%29+for+the+Treatment+of+Herpetic+Keratitis"
  [15]=>
  string(19) "2019-04-02 06:04:47"
  ["add_date"]=>
  string(19) "2019-04-02 06:04:47"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:35:51"
  ["create_at"]=>
  string(19) "2019-05-09 16:35:51"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

FDA Approves Avaclyr (acyclovir ophthalmic ointment) for the Treatment of Herpetic Keratit

NEW YORK–(BUSINESS WIRE) April 01, 2019 –The US Food and Drug Administration (FDA) has approved Fera Pharmac

array(40) {
  [0]=>
  string(4) "2129"
  ["article_id"]=>
  string(4) "2129"
  [1]=>
  string(66) "After Scoring New Capital, Fifth Eye Prepares to Seek FDA Approval"
  ["article_title"]=>
  string(66) "After Scoring New Capital, Fifth Eye Prepares to Seek FDA Approval"
  [2]=>
  string(150) "Fifth Eye, an Ann Arbor-based medical software startup spun out of technology developed at the University of Michigan, today announced that it has rai"
  ["short_description"]=>
  string(150) "Fifth Eye, an Ann Arbor-based medical software startup spun out of technology developed at the University of Michigan, today announced that it has rai"
  [3]=>
  string(368) "Fifth Eye, an Ann Arbor-based medical software startup spun out of technology developed at the University of Michigan, today announced that it has raised $9 million in new investment capital, bringing its total venture backing to date to $11.5 million. The round was led by Arboretum Ventures and Cultivation Capital, with participation from Invest Michigan, […]"
  ["description"]=>
  string(368) "Fifth Eye, an Ann Arbor-based medical software startup spun out of technology developed at the University of Michigan, today announced that it has raised $9 million in new investment capital, bringing its total venture backing to date to $11.5 million. The round was led by Arboretum Ventures and Cultivation Capital, with participation from Invest Michigan, […]"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "37"
  ["rss_id"]=>
  string(2) "37"
  [14]=>
  string(62) "http://feedproxy.google.com/~r/XconomyHealthIT/~3/tto1dOn94xY/"
  ["blog_url"]=>
  string(62) "http://feedproxy.google.com/~r/XconomyHealthIT/~3/tto1dOn94xY/"
  [15]=>
  string(19) "2019-04-02 03:06:22"
  ["add_date"]=>
  string(19) "2019-04-02 03:06:22"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:41:33"
  ["create_at"]=>
  string(19) "2019-05-09 16:41:33"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

After Scoring New Capital, Fifth Eye Prepares to Seek FDA Approval

Fifth Eye, an Ann Arbor-based medical software startup spun out of technology developed at the University of Michigan, t

array(40) {
  [0]=>
  string(4) "1983"
  ["article_id"]=>
  string(4) "1983"
  [1]=>
  string(65) "MHRA Issues Guidance for Air Shipping Medicines in No-Deal Brexit"
  ["article_title"]=>
  string(65) "MHRA Issues Guidance for Air Shipping Medicines in No-Deal Brexit"
  [2]=>
  string(158) "&#nl        The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) released guidance for EU drugmakers shipping medicines by air freight t"
  ["short_description"]=>
  string(158) "&#nl        The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) released guidance for EU drugmakers shipping medicines by air freight t"
  [3]=>
  string(215) "&#nl        The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) released guidance for EU drugmakers shipping medicines by air freight to the UK in the event of a no Brexit agreement.&#nl      "
  ["description"]=>
  string(215) "&#nl        The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) released guidance for EU drugmakers shipping medicines by air freight to the UK in the event of a no Brexit agreement.&#nl      "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "14"
  ["rss_id"]=>
  string(2) "14"
  [14]=>
  string(105) "https://www.fdanews.com/articles/190772-mhra-issues-guidance-for-air-shipping-medicines-in-no-deal-brexit"
  ["blog_url"]=>
  string(105) "https://www.fdanews.com/articles/190772-mhra-issues-guidance-for-air-shipping-medicines-in-no-deal-brexit"
  [15]=>
  string(19) "2019-04-02 02:47:40"
  ["add_date"]=>
  string(19) "2019-04-02 02:47:40"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:35:56"
  ["create_at"]=>
  string(19) "2019-05-09 16:35:56"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

MHRA Issues Guidance for Air Shipping Medicines in No-Deal Brexit

&#nl The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) released guidance for EU drugmake

array(40) {
  [0]=>
  string(4) "1823"
  ["article_id"]=>
  string(4) "1823"
  [1]=>
  string(85) "Another EtO Medical Device Sterilizer to Close Due to Environmental Quality Issues"
  ["article_title"]=>
  string(85) "Another EtO Medical Device Sterilizer to Close Due to Environmental Quality Issues"
  [2]=>
  string(158) "Viant Medical’s Grand Rapids, MI facility was hit with violations from the Michigan Department of Environmental Quality.&#nlThe post Another EtO Medica"
  ["short_description"]=>
  string(158) "Viant Medical’s Grand Rapids, MI facility was hit with violations from the Michigan Department of Environmental Quality.&#nlThe post Another EtO Medica"
  [3]=>
  string(544) "
Viant Medical’s Grand Rapids, MI facility was hit with violations from the Michigan Department of Environmental Quality.
&#nl
The post Another EtO Medical Device Sterilizer to Close Due to Environmental Quality Issues appeared first on MedTech Intelligence.
&#nl"
  ["description"]=>
  string(544) "
Viant Medical’s Grand Rapids, MI facility was hit with violations from the Michigan Department of Environmental Quality.
&#nl
The post Another EtO Medical Device Sterilizer to Close Due to Environmental Quality Issues appeared first on MedTech Intelligence.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "98"
  ["rss_id"]=>
  string(2) "98"
  [14]=>
  string(132) "https://www.medtechintelligence.com/news_article/another-eto-medical-device-sterilizer-to-close-due-to-environmental-quality-issues/"
  ["blog_url"]=>
  string(132) "https://www.medtechintelligence.com/news_article/another-eto-medical-device-sterilizer-to-close-due-to-environmental-quality-issues/"
  [15]=>
  string(19) "2019-04-02 02:32:20"
  ["add_date"]=>
  string(19) "2019-04-02 02:32:20"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-04-15 14:56:01"
  ["create_at"]=>
  string(19) "2019-04-15 14:56:01"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Another EtO Medical Device Sterilizer to Close Due to Environmental Quality Issues

Viant Medical’s Grand Rapids, MI facility was hit with violations from the Michigan Department of Environmenta